The UK Medicines and Healthcare products Regulatory Agency is allowing Roche to make its promising new but as yet unlicensed hemophilia drug, Hemlibra (emicizumab), available to patients under the early access to medicines scheme (EAMS).
The UK's decision to allow patients early access to emicizumab comes as the drug is nearing the final stages of...








